LoadingLoadingLoading26 funds hold it.Insiders net selling.
Net selling: insiders sold $3.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsLast report
Oct 29, 2026
Period ending
Sep 30, 2026
Earnings per share
$1.47 expected
Estimates as of Oct 29, 2026
EPS expected
$1.31 to $1.51
Revenue expected
7 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $1.52est. $1.47 | +3.34%beat | $1.02BSEC filing | +6.0%from $961.1M |
| Jun 30, 2026Reported Jul 30, 2026 | $1.42est. $1.35 | +4.85%beat | $1.03BSEC filing | +6.3%from $966.0M |
| Mar 31, 2026Reported Apr 30, 2026 | $1.19est. $1.15 | +3.48%beat | $982.9MSEC filing | +10.8%from $887.3M |
| Dec 31, 2025Reported Feb 5, 2026 | $1.25est. $1.23 | +1.74%beat | $962.7MAlpha Vantage | +13.5%from $848.1M |
| Sep 30, 2025Reported Oct 30, 2025 | $1.62est. $1.57 | +3.18%beat | $961.1MSEC filing | +5.7%from $909.3M |
| Jun 30, 2025Reported Jul 31, 2025 | $1.66est. $1.59 | +4.40%beat | $966.0MSEC filing | +6.1%from $910.1M |
| Mar 31, 2025Reported May 1, 2025 | $1.20est. $1.16 | +3.45%beat | $887.3MSEC filing | -3.1%from $915.4M |
| Dec 31, 2024Reported Feb 6, 2025 | $1.52est. $1.26 | +20.63%beat | $848.1MAlpha Vantage | +1.1%from $838.5M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $961.1M | $962.7M | $982.9M | $1.03B |
| Cost of what it sold | $673.3M | $701.1M | $706.7M | $740.6M |
| Gross profit | $287.9M | $261.6M | $276.2M | $285.9M |
| What it spent | ||||
| Research and development | $455.2M | $151.3M | $167.6M | $157.7M |
| Sales and admin | $148.8M | $151.3M | $167.6M | — |
| Other operating costs | -$455.2M | -$151.7M | -$167.6M | — |
| Total operating expenses | $148.8M | $151.0M | $167.6M | $157.7M |
| What was left | ||||
| Operating profit | $139.1M | $110.7M | $108.6M | $128.1M |
| Interest on debt | $13.5M | $17.0M | $16.9M | $16.0M |
| Profit before tax | $154.1M | $91.5M | $93.8M | $115.0M |
| Tax | $26.3M | $17.3M | $21.0M | $27.0M |
| Net profit | $127.9M | $74.3M | $72.7M | $87.6M |
| EBITDA | $242.9M | $185.1M | $186.4M | $207.8M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
BullishOct 27Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
BullishOct 27Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
NeutralOct 27Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
BullishOct 27Aptar Pharma Acquires Pulmotree to Expand Pulmonary Drug Delivery Technology
NeutralOct 26Aptar taps packaging executive to run pharma business
Leans bullishOct 26AptarGroup, Inc. Estimates – NYSE:ATR
NeutralOct 24AptarGroup, Inc. (ATR) Interactive Stock Chart - Yahoo Finance
NeutralOct 23
